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Alicja Zientara, MD1, Kirk Graves, ECCP1, Renate Behr, ECCP1,
Michele Genoni, MD1, and Christoph K. Hofer, MD, DESA3
Abstract
Background: Sonoclot is used to measure kaolin-based activated clotting time (kACT) for heparin management. Apart from
measuring kACT, the device assesses the patient’s coagulation status by glass bead–activated tests (gbACTs; measuring also clot
rate [CR] and platelet function [PF]). Recently, a new version of the Sonoclot has been released, and the redesign may result in
performance changes. The aim of this study was to evaluate and compare the performance of the new (S2) and the previous (S1)
Sonoclot. Methods: The S1 was used in the routine management of 30 patients undergoing elective cardiac surgery. Blood
samples were taken at baseline (T1), after heparin administration (200 U/kg, 100 U/kg; T2 and T3), during cardiopulmonary bypass
(T4), after protamine infusion (T5), and before intensive care unit transfer (T6). Kaolin-based activated clotting time and gbACTs
were measured in duplicate by both the old and the new device and performance compared by Bland-Altman analysis and
percentage error calculation. Results: A total of 300 kACT and 180 gbACTs were available. Bland-Altman analysis for kACT
revealed that S2 consistently reported results in shorter time compared to S1 (overall¼14.7%). Comparing S2 and S1, the glass
bead–activated tests showed mean percentage differences of 18.9% (gbACTs), þ37.4% (CR), and 3.7% (PF). Conclusion:
Since clotting is faster in the new S2 compared to S1, shorter clotting times have to be considered in clinical practice. The use of S2
kACT in heparin management will result in higher heparin and protamine dosing unless heparin kACT target values are adjusted
to correct for the differences in results between S1 and S2.
Keywords
Sonoclot, point-of-care devices, viscoelastic measurement, activated clotting time, coagulation, cardiopulmonary bypass, heparin,
cardiac surgery
Introduction
The Sonoclot (Sonoclot Coagulation and Platelet Function
Analyzer; Sienco Inc, Boulder, Colorado) is a viscoelastic
point-of-care coagulation analyzer and provides information
on hemostasis in a qualitative graph and as quantitative results
including activated clotting time (ACT), clot rate (CR), and
platelet function (PF).1 Primarily, Sonoclot is being used to
monitor the adequacy of heparin anticoagulation in the case
of extracorporeal circulation. Furthermore, Sonoclot and other
viscoelastic point-of-care coagulation devices play a pivotal
role in perioperative hemostatic management at the bedside.2
They have been shown to be predictive of postoperative bleed-
ing after cardiopulmonary bypass (CPB) and cost-effective in
perioperative care when combined with protocol-based trans-
fusion strategies.3-5
Until now, the previous version of the Sonoclot (S1) was
used mainly to measure kaolin-based activated clotting times
(kACTs) as a monitor for heparin therapy, additionally allow-
ing the assessment of the patients’ coagulation status by glass
bead–activated tests (gbACTs; depicting also CR and PF).1
Recently, a new version of the Sonoclot (S2) has been devel-
oped to perform different tests simultaneously. Although S2
shares the technical fundamentals with S1, the miniaturization
of the device and the use of a metal cuvette holder instead of
the plastic one in the previous S1 may affect all measurements
(ACT, CR, and PF), resulting in a faster rewarming of blood
samples to 37C. Temperature differences alter the coagulation
function, and therefore, any time delay incurred in rewarming
the blood samples might affect the test results.
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The aim of the present study was to evaluate the perfor-
mance of the new S2 device by focusing on kaolin- and glass
bead–activated measurements in 30 patients. The values were
then compared to the previous S1 device so that the current
heparin management target values may be adjusted for ensur-
ing adequate heparinization with the new device.
Methods
Patients
With approval of the institutional research ethics board
(Kantonale Ethikkommission Zurich, Switzerland; KEK
Nr. StV 1-2007 SPUK Chirurgie), data of 30 consecutive
patients undergoing cardiac surgery at the Triemli City Hos-
pital, Zurich, Switzerland, were analyzed (ClinicalTrials.gov
identifier: NCT02588976). In this prospective, observational
clinical study, elective cardiac surgery patients requiring
CPB with heparin anticoagulation were included. Emer-
gency cardiac surgeries without the use of CPB or with CPB
requiring anticoagulation other than heparin were excluded.
Perioperative Management
In all patients, perioperative routine management (ie, surgery,
anesthesia, CPB, fluid and transfusion therapy) was performed
according to standardized institutional protocols. Cardiopul-
monary bypass was performed with a membrane oxygenator
(Quadrox HMO1010; Maquet Cardiopulmonary AG, Hirlin-
gen, Germany) under moderate hypothermia (28C-32C) with
pump flow rates of 2.2 to 2.4 L/min/m2. The protocol of
heparin management for CPB was guided by the Sonoclot ana-
lyzer (S1) using kACT test; anticoagulation was achieved with
heparin 200 U/kg þ 100 U/kg IV heparin (Liquemin; Drossa-
pharm AG, Basel, Switzerland), according to Bull et al in order
to maintain the kACT above 480 seconds.6 Additional 10 000
U of heparin were added to the priming volume of the circuit.
At the end of the procedure, heparin was reversed by giving
protamine (Protamine; MEDA Pharmaceuticals GmbH, Wan-
gen-Bru¨ttisellen, Switzerland) up to a maximum dose of 1 mg/
100 U of the total heparin dose. In this study, all patients
received the same batches of heparin and protamine. As part
of our institutional coagulation management algorithm to direct
hemostatic therapy, Sonoclot’s glass bead–activated test was
additionally being measured in the perioperative setting.
Sonoclot Coagulation and Platelet Function Analyzer
Detailed aspects of the Sonoclot technology have been
described previously.1 The new version of the Sonoclot (S2,
model SCP1-4) was developed to convert the previous version
of the single-channel Sonoclot (S1, model DP-2951) into
instruments with 1, 2, or 4 output channels in order to perform
different tests simultaneously. Additionally, the new S2 has
several technical changes in mechanical design, electronics,
and software. The S2 is considerably smaller than the S1, and
a major modification in the S2 is that it is equipped with a metal
cuvette holder instead of the plastic one in the S1. This helps in
improved heat transfer to the blood sample, thereby resulting in
a faster rewarming of blood samples to 37C. At the beginning
of the test, the temperature of blood samples may be reduced by
5C or more due to the handling of collection syringes and
dispensing cannulas. This temperature change can impair the
existing coagulation function and, therefore, any time delay
incurred in rewarming the blood samples can affect the test
results. The faster the sample rewarms, the interference of the
temperature variance in the results is reduced. The disposa-
bles, reagents, sample and reagent volumes used and the tim-
ing are identical for the old and new device. Their parts and
the part numbers are the same. The reagents include separate
healthy reference range values for old and new instruments.
Furthermore, the manufacturer instructs the users to compare
their current heparin management instrumentation and the S2
to establish control values that match the institution’s current
heparin management target values for ensuring adequate
heparinization. The viscoelastic output and the clot signal of
both the S1 and S2 are calibrated to the same viscosity stan-
dards, providing the same viscoelastic measurement of the
developing clot.
Measurement Time Points
Blood samples were taken at induction of anesthesia (T1, base-
line), before initiation of CPB 3 minutes after initial heparin
administration of 200 U/kg (T2), 3 minutes after the second
dose of heparin 100 U/kg (T3), 20 minutes during CPB (T4), at
the end of the procedure after protamine infusion (T5), and
before intensive care unit (ICU) transfer (T6). All Sonoclot
measurements were performed in duplicates using S1 and S2
at the same time: kACT was measured at T1 through T5; glass-
bead tests were done at baseline (T1) and after heparin reversal
Table 1. Sociodemographic and Procedure-Related Data.
Patients
Female/male ratio (n/n) 16/14
Age, years 67.3+ 15.4
BMI, kg/m2 27.1+ 5.2
Euroscore 7.3+ 3.2
LVEF, % 55.6+ 3.2
Procedures
AVR, n (%) 12 (40)
MVR, n (%) 2 (7)
CompG, n (%) 3 (10)
Combined, n (%) 13 (43)
OP time, minutes 263+ 108
CPB time, minutes 106+ 34
ACC time, minutes 65+ 24
ANA time, minutes 379+ 107
ICU stay, days 2.9+ 0.50
Abbreviations: ACC, aortic cross clamping; ANA, anesthesia; AVR, aortic valve
replacement; BMI, body mass index; CompG, composite graft; Combined,
combined valve procedures; CPB, cardiopulmonary bypass; ICU, intensive care
unit; LVEF, left ventricular ejection fraction; MVR, mitral valve reconstruction;
OP, operation.
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(T5 and T6) using both the old and the new device. Apart from
these measurements, further kACTs were performed with the
Sonoclot S1 if clinically indicated.
Statistical Analyses
Statistical analysis was performed using IBM SPSS Statistics
2.0, release 20.0.0 (IBM Corporation Armonk, New York) and
Sigmaplot 12.0 (Systat Software Inc.; San Jose, California).
Power analysis was performed to yield a potentially signif-
icant difference between measurements performed by S1 and
S2: based on the extensive experience using S1, a large varia-
tion in the normally distributed values of ACT measurements
before, during, and after CPB can be expected. For ACT, a
mean difference of 20 + 60 seconds, an a-error level of .05,
and a sample size of 30 patients were needed to achieve an
adequate test power of >80%.
Student t test was applied, and Bland-Altman analysis was
performed in order to compare S1 and S2 measurements. The
difference in measurements between the 2 devices was plotted
against the average of the 2 measurements. The mean differ-
ence is the bias, whereas limits of agreement are obtained by
subtracting and adding twice the standard deviation (SD) of
the mean difference. The lower and the upper limit designate a
prediction interval in which in 95% the difference between the
2 devices will lie assuming constant bias and variability. Per-
centage deviation (ie, percentage error) reflects limits of
agreement in relation to the average measurements of the 2
devices. A P value  .05 was considered to be statistically
significant. Unless otherwise indicated, data are given as
mean value + SD.
Results
Sociodemographic and procedure-related data of all 30 patients
undergoing elective cardiac surgery are summarized in Table 1.
Three hundred duplicate kACT and 180 glass bead–activated
measurements were performed using S1 and S2, thus 150 and
90 matched data sets were obtained for statistical analysis.
Kaolin-Activated Measurements
The kACTs ranged from 60 to 950 seconds for S1 and from
60 to 701 seconds for S2, with a significant difference at
each measurement point (T1-5, P < .001; Table 2). Test
variability for S1 and S2 was within 6.1% to 10.6% and
3.7% to 6.3%, respectively (P ¼ .026; Table 2). Bland-
Altman analysis revealed a consistent underestimation of
kACT measured by S2 as compared to S1 with a range of
14 to 104 seconds (Table 2, Figure 1). Percentage devia-
tion (ie, percentage error) values between 10.5% and
18.5% were observed (Figure 3).
Glass Bead–Activated Measurements
For gbACTs, a range of 93 to 540 seconds were observed for
S1 and 54 to 384 seconds for S2. There was a significant
Table 2. Comparison of kACT Measurements by Sonoclot S1 and S2.a
T1 T2 T3 T4 T5 Overall
Previous Sonoclot (S1)
kACT, seconds 127 + 19 300+ 54 436 + 119 564+ 147 115 + 20 309 + 211
Test variability, % 6.9 + 8.0 10.6+ 9.2 9.2 + 8.2 7.9+ 14.1 6.1 + 7.9 7.7+ 9.8
New Sonoclot (S2)
kACT, seconds 102 + 13 248+ 57 367 + 29 460+ 105 102 + 13 257 + 168
Test variability, % 6.3 + 6.9 3.7+ 2.8 5.6 + 5.1 6.1+ 7.0 4.2 + 3.1 5.4+ 5.6
Bland-Altman analysis
Mean bias+ LoA, seconds 25 + 30 52+ 52 64 + 118 104+ 103 14 + 28 52 + 134
Abbreviations: CPB, cardiopulmonary bypass; ICU, intensive care unit; kACT, kaolin-activated clotting time; LoA, limits of agreement (¼ 1.95  standard
deviation).
aMeasurement time points: baseline at induction of anesthesia (T1), before initiation of cardiopulmonary bypass, that is, 3 minutes after initial heparin admin-
istration of 200 U/kg (T2), 3 minutes after the second dose of heparin 100 U/kg (T3), 20 minutes during CPB (T4), at the end of the procedure after protamine
infusion (T5), and before ICU transfer (T6).
Figure 1. Bland-Altman analysis for kACT measurements by the
previous (S1) and new (S2) Sonoclot Analyzer. kACT indicates kaolin-
activated clotting time; solid line, mean bias; dashed line, limits of
agreement (¼ 1.95  standard deviation).
22 Clinical and Applied Thrombosis/Hemostasis 23(1)
difference between S1 and S2 at all measurement points (T1,
T5, and T6, P < .001; Table 3). Clot rates were between 3.2 and
27.5 Units (S1) and between 4.9 and 44.5 Units (S2,
P < .001; Table 3). Platelet function ranged from 1 to 4.5
and from 0.6 to 4.3 for S1 and S2, respectively (P < .05;
Table 3). A low test variability could be demonstrated for
gbACTs and CR which are assessed by both S1 and S2,
whereas the variability of PF was higher (Table 3). There
was no significant difference regarding the test variability of
S1 and S2 (ACT: P ¼ .113, CR: P ¼ .780, PF: P ¼ .831).
Compared to S1, the S2 demonstrated gbACT underestima-
tion and CR overestimation, which was observed using the
Bland-Altman analysis (Figure 2). The overall effects on PF
were small, but there was a tendency for overestimation at
T1 and underestimation at T2 and T3. The corresponding
percentage error values are presented in Figure 4.
Discussion
The new Sonoclot device, S2, can rewarm the blood specimens
in the test cuvette in a faster manner. Thereby, kACT values
measured using S2 were lower on average (15%) compared
to that using S1, underestimating kACT by 14 to 104 sec-
onds. This faster rewarming of blood samples using S2 showed
lower gbACTs (19%) and higher CR (þ37%) values. In addi-
tion, values measured by the new S2 were more reliable as
expressed by a lower test variability.
A variety of mechanisms lead to overt thrombin formation
during CPB, which can activate and consume critical hemo-
static components including platelets, fibrinogen, and other
coagulation factors.7 Paradoxically, inadequate anticoagulation
during CPB can lead to a profound coagulopathy, likely due to
disseminated intravascular coagulation, upon its termination.8
Additionally, it has been shown that the perioperative coagula-
tion status has a direct impact on postoperative blood loss and
that coagulopathy is the main driver for excessive perioperative
bleeding and blood product use.9 Consequently, the warranty of
adequate anticoagulation during CPB and targeted procoagula-
tory therapy thereafter is one of the basic efforts to improve
perioperative outcome.
Historically, in 1957, the Mayo Clinic described preven-
tion of the coagulation of blood for the Gibbon-type pump
oxygenator, prescribing 3 mg of heparin (300 U) per kilogram
of patient body weight.10 Monitoring heparinization by the
ACT of whole blood was first reported by Hattersley in
1966.11 Bull et al then popularized the concept of the safe
zone for anticoagulation during CPB in the mid-1970s,
Figure 3. Percentage error (% error) for kACT of the new Sonoclot
Analyzer (S2) compared to the previous Sonoclot Analyzer (S1).
kACT indicates kaolin-activated clotting time.
Figure 2. Bland-Altman analysis for glass bead–activated measure-
ments by the previous (S1) and new (S2) Sonoclot Analyzer. gb indi-
cates glass-bead activation; ACT, activated clotting time; CR, clot rate;
PF, platelet function; solid line, mean bias; dashed line, limits of
agreement (¼ 1.95  standard deviation).
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defining this as an ACT between 300 and 600 seconds.12 In
1975, von Kaulla et al described the Sonoclot Analyzer, a
device that measures the changing impedance to movement
imposed by the developing clot on a small probe vibrating at
an ultrasonic frequency in coagulating blood sample.13 Based
on this evolution, the practical point-of-care testing was
imported into the operating department for monitoring
anticoagulation.
The kACT measurement is a clinical standard for heparin
management during CPB.8,14,15 In our investigations, kACT
measurements showed a significant difference between the 2
Sonoclot generations ranging from 60 to 950 seconds for the
previous S1 and from 60 to 701 seconds for the new S2. Trans-
ferred to clinical practice, patients managed with kACT using
S2 would receive higher heparin and protamine dosing, unless
reference values were specifically adjusted for the new Sono-
clot device.
Apart from heparin management, Sonoclot is being used
to assess further aspects of the patient’s coagulation status
such as platelet function. For example, the device has shown
to reliably detect pharmacological glycoprotein IIb/IIIa
receptor inhibition.16 However, to obtain accurate results,
cuvettes containing glass beads for specific coagulation and
platelet activation should be used.1 In our studies, gbACTs
showed the same tendency like kACT measurements; using
S1, the gbACTs ranged from 93 to 540 seconds and from 54
to 384 seconds for S2, and the CR values were between 3.2
and 27.5 Units (S1) and 4.9 and 44.5 Units (S2). For PF,
this consistency could not be shown, and PF by S2 tended to
overestimate S1 at the initial measurement time point but
underestimated S1 at the postoperative time points.
Recently, the clinical relevance has been shown that Sono-
clot might predict postoperative bleeding in patients under-
going cardiac surgery.4 Especially glass bead measurements
by Sonoclot were predictive after heparin reversal and before
chest closure, which is comparable to the measurement point
T5 in our study. Transferred to postoperative management in
the ICU, shorter ACT and faster CR might complicate the
identification of a potential postoperative bleeding tendency.
Therefore, reference values for ACT, CR, and PF for daily
clinical use in treatment algorithms have to be adapted for the
new S2 machine.
Focusing on the technical and procedural realities, former
studies described different responses of ACT under similar
conditions using the same type of activator but manufactured
by different companies.17 In the present study, we used the
same coagulation activator in 2 different generations of the
same device. By taking the blood samples simultaneously
from the same patient, classical bias such as hypothermia,
inadequate specimen warming, hemodilution, platelet
abnormalities, or aprotinin infusion could be reduced or com-
pletely avoided.18-20 Regarding the reengineered and mini-
mized design of the S2, the question about the technical
differences between S1 and S2 remains and may lead to the
explanation of the aforementioned results. Beside the minia-
turization of the S2, another main innovation is in replacing
the plastic cuvette holder in S1 with a metal one. This change
results in a faster rewarming of blood samples to 37C and
Table 3. Comparison of Glass Bead–Activated Tests by Sonoclot S1 and S2.
T1 T5 T6 Overall
Previous Sonoclot (S1)
gbACTs, seconds 196+ 31 291 + 94 241 + 54 242+ 75
Test variability, % 6.4 + 6.9 14.6 + 22.4 4.1+ 4.3 8.4+ 14.4
CR 20.1+ 5.1 8.4 + 3.2 16.0+ 4.3 14.8+ 6.4
Test variability, % 9.6 + 7.2 10.9 + 12.9 9.3+ 7.2 9.9+ 9.3
PF 2.7+ 0.9 2.2 + 0.7 3.2+ 0.5 2.7+ 0.8
Test variability, % 28.6+ 26.6 26.2 + 17.5 17.8+ 13.9 24.2+ 20.4
New Sonoclot (S2)
gbACTs, seconds 165+ 24 234 + 65 196 + 47 195+ 57
Test variability, % 4.6 + 3.6 6.9 + 7.1 5.7+ 5.8 5.8+ 5.7
CR 29.8+ 7.5 12.2 + 5.3 24.6+ 8.9 22.1+ 10.4
Test variability, % 7.6 + 8.2 12.8 + 9.7 8.3+ 7.32 9.6+ 8.7
PF 2.9+ 0.8 1.9 + 0.9 2.5+ 0.8 2.5+ 0.9
Test variability, % 26.8+ 27.1 25.8 + 24.3 17.8+ 18.7 23.5+ 23.6
Bland-Altman analysis
gbACTs
Mean bias+ LoA, seconds 40+ 26 57 + 96 45 + 42 48+ 63
CR
Mean bias+ LoA 9.6+ 8.3 3.8 + 6.1 8.5+ 5.5 7.3+ 9.9
PF
Mean bias+ LoA 0.3+ 1.8 0.3 + 1.2 0.7+ 1.5 0.2+ 1.7
Abbreviations: gb, glass bead; ACT, activated clotting time; CR, clot rate; ICU, intensive care unit; PF, platelet function; LoA, limits of agreement (¼ 1.95 
standard deviation).
aMeasurement time points: baseline at induction of anesthesia (T1), at the end of the procedure after protamine infusion (T5), and before ICU transfer (T6).
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may thereby explain the faster clotting in S2. With the
improved and faster temperature regulation in the new S2
instrument, the sample temperature variance as a component
of test result error will significantly be reduced.
In summary, during CPB profound anticoagulation is
required in order to both prevent thrombus formation within
the circuit and patient and avoid the depletion of hemostatic
factors by overt and uncontrolled coagulation activation. In the
present study, the new Sonoclot S2 consistently reported faster
kACT and gbACT results compared to the previous Sonoclot
S1. These differences have clinical implications, for example,
the use of S2 kACT for heparin management will result in
higher heparin and protamine dosing unless kACT target val-
ues are adjusted to correct for the differences in results between
S1 and S2. Further studies are needed to assess the clinical
significance and outcome in patients managed by the new
Sonoclot S2 machine.
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